• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis.
CONCLUSIONS: ACEi/ARB and MRA can be safely used in CA, provided that no contraindications are present, treatment is started at a low dose and slowly up-titrated, and patients are monitored quite closely. Beta-blocker therapy is less tolerated in patients with AL amyloidosis and/or worse haemodynamic function. PMID: 32475765 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - May 27, 2020 Category: Internal Medicine Authors: Aimo A, Vergaro G, Castiglione V, Rapezzi C, Emdin M Tags: Eur J Intern Med Source Type: research

One-year clinical events and management of patients with atrial fibrillation hospitalized in cardiology centers: Data from the BLITZ-AF study.
CONCLUSIONS: The follow-up of the BLITZ-AF study provide an up to date picture of the clinical course of patients with AF, who appear frequently affected by heart failure and severe comorbidities which might have led to the high mortality rate. PMID: 31952984 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - January 13, 2020 Category: Internal Medicine Authors: Cemin R, Colivicchi F, Maggioni AP, Boriani G, De Luca L, Di Lenarda A, Di Pasquale G, Fabbri G, Lucci D, Gulizia MM, On the behalf of BLITZ-AF Investigators Tags: Eur J Intern Med Source Type: research

Medication use in long-term survivors from the MONICA/KORA Myocardial Infarction Registry.
CONCLUSION: SPM use several years after AMI was high and associated with treatment at index AMI and patients' comorbidities. PMID: 28826823 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - August 18, 2017 Category: Internal Medicine Authors: Amann U, Kirchberger I, Heier M, Thilo C, Kuch B, Meisinger C Tags: Eur J Intern Med Source Type: research